Skip to content
TAK·NYSE·US

Takeda

Takeda is a global biopharmaceutical company that develops, manufactures, and markets prescription medicines across gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Its revenue is driven primarily by branded specialty drugs and biologics sold into hospital, specialist, and public-health channels.

Recent Activity

Updated Sep 24, 2026
–The FDA accepted Takeda's New Drug Application for zasocitinib under priority review for psoriasis.

Past updates are part of the Pro plan.

Thematic Position

TAK

Relationship Groups

Suppliers2
Customers5
Partners10
Licensing19
Competitors20

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

6 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

sanctionsexport control
OFAC general license framework governs limited Takeda sales in Iran
SEC 20-FJun 17, 2026

The full regulatory passage is part of the Pro plan.

11 more · Regulatory and geopolitical insights are part of the Pro plan.

Disclosed customers above 10% of revenue

2 customers · Named major customers are part of the Pro plan.